日本纳武利尤单抗相关重症肌无力伴肌炎和心肌炎的临床特征
基于日本上市后监测数据库,2014年9月至2016年8月接受纳武利尤单抗或伊匹木单抗单药治疗的10,277例癌症患者中,纳武利尤单抗组9,869例出现12例(0.12%)重症肌无力,伊匹木单抗组408例无病例。这些患者起病早、病情重,球部症状和肌无力危象较特发性重症肌无力更常见,血清肌酸激酶平均显著升高至4,799 IU/L,部分合并肌炎或心肌炎,免疫抑制治疗有效但仍有2例死亡。
要点
- 纳武利尤单抗治疗患者中重症肌无力发生率约0.12%,伊匹木单抗组未见病例。
- 纳武利尤单抗相关重症肌无力起病早、进展快,球部症状和肌无力危象更常见。
- 血清肌酸激酶显著升高提示可能合并肌炎或心肌炎,需及时识别并免疫抑制治疗。
核心结论
- 纳武利尤单抗相关重症肌无力虽罕见但病情严重,常伴肌炎和心肌炎,需及时正确识别。
研究设计与样本
- 基于日本上市后监测的2年安全性数据库,纳入10,277例接受纳武利尤单抗或伊匹木单抗单药治疗的癌症患者,并以105例特发性重症肌无力患者为对照。
主要发现
- 纳武利尤单抗组9,869例中报告12例(0.12%)重症肌无力,伊匹木单抗组408例中无病例。
- 12例患者中6男6女,平均年龄73.5±6.3岁,起病于纳武利尤单抗治疗后早期并迅速恶化。
- 纳武利尤单抗相关重症肌无力患者中球部症状和肌无力危象较特发性重症肌无力更常见。
- 10例抗乙酰胆碱受体抗体阳性,血清肌酸激酶平均显著升高至4,799 IU/L。
- 12例中4例合并肌炎、3例合并心肌炎(1例同时合并两者),免疫抑制治疗有效,4例达到药物缓解或微小表现,但2例死亡。
临床怎么用
- 对接受免疫检查点抑制剂治疗的癌症患者,应警惕重症肌无力的早期表现,及时识别并启动免疫抑制治疗。
局限性
- 研究基于日本上市后监测数据库,为回顾性观察性设计,可能存在报告偏倚和信息不完整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report the clinical features of myasthenia gravis (MG) induced by treatment with immune checkpoint inhibitors using 2-year safety databases based on postmarketing surveys in Japan. METHODS: We studied 10,277 patients with cancer who had received monotherapy with either nivolumab or ipilimumab between September 2014 and August 2016. As the control group, 105 patients with idiopathic MG were used. RESULTS: There were 12 MG cases (0.12%) among 9,869 patients with cancer who had been treated with nivolumab, but none among 408 patients treated with ipilimumab. These 12 patients included 6 men and 6 women with a mean age of 73.5 ± 6.3 years. MG onset occurred in the early phase after nivolumab treatment and rapidly deteriorated. Nivolumab-related MG (nivoMG) included 4 patients with mild involvement and 8 patients with severe involvement. Bulbar symptoms and myasthenic crisis were observed more frequently in nivoMG than idiopathic MG. Ten patients were positive for anti-acetylcholine receptor antibodies. Serum creatine kinase levels were markedly elevated to an average level of 4,799 IU/L. Among the 12 patients with nivoMG, 4 had myositis and 3 had myocarditis, with 1 of these patients having both. Immunosuppressive therapy was effective. Postintervention status showed that pharmacologic remission or minimal manifestations were obtained in 4 patients; however, 2 patients died. Immune-related adverse events triggered by nivolumab impaired the patients' daily living activity. CONCLUSIONS: The prompt and correct recognition of MG following treatment with immune checkpoint inhibitors in patients with cancer is important.
引用
- Suzuki S, Ishikawa N, Konoeda F, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 2017. PMID: 28821685. doi:10.1212/WNL.0000000000004359
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。